YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
YPF SA (NYSE:YPF) is seeing a surge in bullish options activity today. So far, 31,000 calls have crossed the tape, compared to just 27 puts. Overall options volume is running at 10.3 times the usual daily amount, while call volume is 37 ti…
CG Oncology stock has delivered very strong 1 year gains, yet the broader valuation checks and current pricing leave investors weighing how much of the story is already reflected in the share price. The stock is up 160.2% over the past yea…
CG Oncology Inc. DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fit…
By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at…
The oncolytic virus cancer therapy market is poised for significant growth, driven by increasing research and development of genetically engineered viruses that selectively target and destroy cancer cells while stimulating anti-tumor immun…
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. Thi…
CG Oncology Inc. PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-term BLA completion for HR BCG-unresponsive NMIBC expected fourth quarter 2026…
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON) breached their fiduciary duties to shareholders. Th…
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.02%, and the actively tr PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
CG Oncology Inc. Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer DALLAS, July 27…
DALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec monotherapy in patients with h…
(RTTNews) - "If you aren't willing to own a stock for 10 years, don't even think about owning it for 10 minutes." - Warren Buffett. The Oracle of Omaha's timeless advice reminds us that patience is one of the key principles of investing. T…
ANI Pharmaceuticals, Inc. Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichment ANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of th…
Shares of CG Oncology CGON have risen 12% over the past three months against the industry's 1.1% decline, primarily driven by growing investor optimism around its lead bladder cancer therapy, cretostimogene grenadenorepvec, accelerating re…
Every investor is looking for opportunities, but finding promising stocks and deciding when to buy is rarely a simple task. Successful investing often depends on separating temporary market moves from businesses that offer meaningful long-…
DENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on surgery, radiation, and chemo…
The non-muscle invasive bladder cancer market is witnessing significant growth due to the rising global incidence of bladder cancer, advancements in immunotherapy, targeted treatments, and launch of novel therapies such as CG0070 (cretosti…
Some tech stocks look way too expensive, investor David Giroux says, but not most of the "Magnificent Seven." - Getty Images/iStock This sure is a tricky time to navigate the stock market. For guidance, I recently turned to veteran investo…
CG Oncology, Inc. has agreed to the separation of President & Chief Operating Officer Ambaw Bellete effective June 30, 2026, while appointing CEO Arthur Kuan as President and launching a search for a Chief Commercial Officer. This consolid…
CG Oncology Inc. DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Gl…
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
CG Oncology Inc. Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Last year’s awardees recently present…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. CG Oncology (CGON) shares have come under pressure even as fresh Phase 2 CORE-008 Cohort CX data in high-risk non-muscl…
CG Oncology Inc. - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat populati…
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat population was 96.0% at 3…
CG Oncology Inc. -First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented- -Visit CG Oncology at booth #3051- DALLAS, May 11, 20…
CG Oncology, Inc. (NASDAQ:CGON) is one of the best performing healthcare stocks so far in 2026. RBC Capital lifted the price target on CG Oncology, Inc. (NASDAQ:CGON) to $79 from $73 on April 27, reaffirming an Outperform rating on the sha…
CG Oncology reported past first-quarter 2026 results with revenue of US$1.08 million, a wider net loss of US$60.20 million, and loss per share of US$0.71, while outlining progress on regulatory filings and clinical programs in non-muscle i…
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to a loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items. T…
* CG Oncology press release [https://seekingalpha.com/pr/20507681-cg-oncology-reports-first-quarter-2026-financial-results-and-provides-business-updates] (CGON [https://seekingalpha.com/symbol/CGON]): Q1 GAAP EPS of -$0.71. * Revenue of $1…
CG Oncology Inc. Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermed…
Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC a…
June S&P 500 E-Mini futures (ESM26) are trending up +0.46% this morning as investors shrugged off an exchange of fire between the U.S. and Iran and awaited the release of the key U.S. jobs report. The U.S. military said on Thursday that Ir…
Gilead Sciences (GILD) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $1.89 per share. This compares to earnings of $1.81 per share a year ago. These figures are adjusted for non-recurring item…
Shares of CG Oncology, Inc. (CGON) have gained 0.2% over the past four weeks to close the last trading session at $67.7, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any…